Biohaven's Q3 update: FDA accepts Vyglxia filing, SK Biopharmaceuticals deal pendingOct 29Quarterly updateBiohaven Ltd.
FDA accepts Biohaven's resubmitted NDA for troriluzole in spinocerebellar ataxiaOct 22Regulatory milestoneBiohaven Ltd.
Biohaven licenses IgG degrader portfolio to Ono Pharma for Asian marketsOct 15PartnershipBHV-1300Biohaven Ltd.
FDA places partial clinical hold on Biohaven's BHV-7000 epilepsy programSep 9Regulatory milestoneBHV-7000Biohaven Ltd.
Biohaven files license and assignment agreements for SK Biopharmaceuticals Kv7 dealAug 26PartnershipBiohaven Ltd.
Biohaven advances degrader and epilepsy pipelines, reports Q2 2026 resultsAug 10Quarterly updateBHV-1300Biohaven Ltd.